The US Food and Drug Administration (FDA) has granted Fast Track designation to Enterome’s EO2463 for the treatment of follicular lymphoma in the low-tumor-burden “watch-and-wait” setting.
Follicular lymphoma (FL), a slow-growing form of non-Hodgkin lymphoma, often presents with few symptoms in its early stages. Many patients are placed under observation until the disease progresses or symptoms appear—a strategy known as “watch-and-wait.” Despite being diagnosed with cancer, these patients typically receive no treatment, leaving a gap in therapeutic options for managing the disease during its indolent phase.
“The FDA’s decision is an important validation of the unique potential of Enterome’s OncoMimics program,” said Pierre Belichard, CEO of Enterome. “It will expedite the clinical development and regulatory pathways for EO2463, which is ready to enter registrational testing as early as next year after this Fast Track designation and a recent positive Type-C meeting with the FDA.”
The Fast Track pathway is designed to accelerate the review of investigational therapies that address serious conditions and fill unmet medical needs. It provides companies with greater access to the FDA through more frequent meetings, rolling submissions, and eligibility for priority review once pivotal data are available.
Clinical Data
EO2463 is now poised to enter a Phase III “watch-and-wait” registrational trial in 2026, following promising results from earlier studies. Interim data from the ongoing Phase I/II SIDNEY trial (NCT04669171) demonstrated marked efficacy and excellent tolerability of EO2463 monotherapy in patients with follicular lymphoma. The therapy showed clinical activity even before being combined with standard treatments, suggesting intrinsic anti-lymphoma effects.
In June 2025, Enterome presented data from the SIDNEY trial showing that 60% of patients with relapsed or refractory follicular or marginal zone lymphoma achieved complete responses when EO2463 was combined with lenalidomide and rituximab (the “R2” regimen). Notably, partial responses were observed within the first six weeks of EO2463 monotherapy, before the addition of R2, highlighting its standalone therapeutic potential. The results exceeded historical response rates associated with R2 therapy alone.
EO2463 represents a novel, off-the-shelf active immunotherapy designed to mimic tumor-associated antigens using microbial-derived peptides. It combines four synthetic peptides corresponding to B cell markers—CD20, CD22, CD37, and CD268 (BAFF receptor)—that display molecular mimicry to trigger targeted immune responses against malignant B lymphocytes. The formulation also includes a universal cancer helper peptide, UCP2, to enhance immune activation.
This approach allows EO2463 to selectively target and destroy malignant B cells while minimizing the risk of immune resistance mechanisms such as antigen escape. By focusing on multiple B cell markers simultaneously, the therapy aims to deliver broad efficacy with a favorable safety profile.
Enterome’s pipeline
Beyond follicular lymphoma, Enterome sees broad potential for EO2463 across various hematologic malignancies. The company’s OncoMimics platform leverages the concept of molecular mimicry, identifying microbial peptides that closely resemble tumor antigens, to elicit precise anti-tumor immune responses. This mechanism underpins a pipeline of novel cancer immunotherapies, including EO4010, which is currently in Phase 1/2 trials for metastatic colorectal cancer.
In addition to its clinical milestones, Enterome has strengthened its financial position to support late-stage development. In June 2025, the company raised $19 million in new financing, including $9 million from the Institute for Follicular Lymphoma Innovation (IFLI) and contributions from several existing investors such as The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP), SymBiosis Capital Management, and Seventure Partners.
